RVMD director sells shares, exercises stock options
Revolution Medicines director Sushil Patel reported option exercises and share sales in RVMD stock.
Rhea-AI Filing Summary
Revolution Medicines director Sushil Patel reported option exercises and share sales in RVMD stock. On June 29, 2026, he exercised stock options to acquire 2,955 shares of common stock at an exercise price of $37.54 per share and sold 5,580 shares in a series of open-market transactions.
The sales were executed at weighted-average prices within ranges from $182.93 to $192.64 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. After these transactions, Patel directly held 21,656 common shares, including 1,191 restricted stock units.
Positive
- None.
Negative
- None.
Insights
Patel’s Form 4 shows a planned option exercise and modest net share sale.
Director Sushil Patel exercised options for 2,955 shares at an exercise price of $37.54 and sold 5,580 shares of Revolution Medicines common stock in multiple open-market trades on June 29, 2026. The filing shows a mix of acquisition and disposition activity.
A footnote states the transactions were made under a Rule 10b5-1 trading plan adopted on March 30, 2026, indicating the trades were pre-scheduled rather than opportunistic. Following the transactions, Patel held 27,236 shares directly, including 1,191 restricted stock units, suggesting he retains a meaningful equity stake.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
11 txns
Insider
Patel Sushil
Role
Director
Sold
5,580 shs ($1.05M)
Approx. gross sale proceeds
$1.05M
Approx. exercise cost
$111K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,955 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,955 | $37.54 | $111K |
| Sale | Common Stock | 300 | $183.1733 | $55K |
| Sale | Common Stock | 900 | $184.5869 | $166K |
| Sale | Common Stock | 1,100 | $185.8991 | $204K |
| Sale | Common Stock | 858 | $186.9157 | $160K |
| Sale | Common Stock | 300 | $187.8267 | $56K |
| Sale | Common Stock | 100 | $188.57 | $19K |
| Sale | Common Stock | 600 | $190.545 | $114K |
| Sale | Common Stock | 541 | $191.8661 | $104K |
| Sale | Common Stock | 881 | $192.6139 | $170K |
Holdings After Transaction:
Stock Option (Right to Buy) — 13,000 contracts (Direct);
Common Stock — 21,656 shares (Direct)
Footnotes (11)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026.
- F2. Includes 1,191 restricted stock units.
- F3. The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4. The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5. The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6. The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7. The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8. The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9. The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F10. The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F11. Fully vested.
Key Figures
Shares sold: 5,580 shares
Option shares exercised: 2,955 shares
Exercise price: $37.54 per share
+5 more
8 metrics
Shares sold
5,580 shares
Total common shares sold in open-market transactions on June 29, 2026
Option shares exercised
2,955 shares
Common shares acquired via stock option exercise on June 29, 2026
Exercise price
$37.54 per share
Exercise price for stock options converted into 2,955 common shares
Sale price ranges
$182.93–$192.64 per share
Price ranges for multiple open-market sale trades reported in footnotes
Post-transaction holdings
27,236 shares
Common shares directly held by Patel after transactions, including RSUs
Restricted stock units
1,191 RSUs
Restricted stock units included within Patel’s reported share holdings
Rule 10b5-1 plan adoption date
March 30, 2026
Date Patel adopted the trading plan governing these transactions
Option expiration
June 19, 2034
Expiration date for the stock option covering 2,955 shares
Key Terms
Rule 10b5-1 trading plan, restricted stock units, weighted average sale price, Stock Option (Right to Buy), +2 more
6 terms
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"Includes 1,191 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"The price reported in Column 4 above reflects the weighted average sale price."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transactions did RVMD director Sushil Patel report on June 29, 2026?
Sushil Patel reported exercising options for 2,955 Revolution Medicines shares and selling 5,580 common shares on June 29, 2026. The sales occurred in multiple open-market trades at prices mainly between $182.93 and $192.64 per share, according to the Form 4 filing.
Were Sushil Patel’s RVMD stock sales under a Rule 10b5-1 trading plan?
Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. Such plans pre-schedule trades, indicating the timing was arranged in advance rather than based on short-term market conditions.
What stock options did Sushil Patel exercise in the latest RVMD Form 4?
Patel exercised stock options covering 2,955 shares of Revolution Medicines common stock at an exercise price of $37.54 per share. A related derivative entry describes a stock option (right to buy) tied to these underlying shares, with the option expiring on June 19, 2034.
AI-generated analysis. How Rhea-AI works. Not financial advice.
